Meeting report VLPNPV: Session 8: Vaccines I

In Session 8 of the recent conference "Virus-Like Particle and Nano-Particle Vaccines" held at the Salk Institute in La Jolla, California (05 June 2014), four scientists described new virus-like particle (VLP) approaches, progress, and early-stage plans for vaccines against significant hum...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2014-10, Vol.10 (10), p.3078-3079
Main Author: Thiriot, David S
Format: Article
Language:English
Subjects:
AIDS Vaccines - immunology
Bacteriophages - immunology
Capsid Proteins - immunology
Dengue Vaccines - immunology
Epitopes - immunology
Humans
Malaria Vaccines - immunology
Meeting Report
Nanoparticles
Papillomavirus Vaccines - immunology
Recombinant Fusion Proteins - immunology
Respiratory Syncytial Virus Vaccines - immunology
Vaccines, Virus-Like Particle - immunology
Vaccines, Virus-Like Particle - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In Session 8 of the recent conference "Virus-Like Particle and Nano-Particle Vaccines" held at the Salk Institute in La Jolla, California (05 June 2014), four scientists described new virus-like particle (VLP) approaches, progress, and early-stage plans for vaccines against significant human pathogens including HPV, malaria, HIV, Dengue, and RSV. A unifying theme was that displaying epitopes in an array on a virus-like particle can be a powerful approach for achieving a strong immune response. VLP approaches described included display of epitopes on bacteriophage, display of epitopes as fusions with other protein multimerization domains, and self-assembly of recombinantly-expressed virus coat proteins. Another theme in some of the presentations was the targeting of neutralizing epitopes that are masked or only transiently accessible during natural infection.
ISSN:2164-5515
2164-554X
DOI:10.4161/21645515.2014.972841